Literature DB >> 22621635

Ruxolitinib for myelofibrosis.

Ibrahim C Haznedaroglu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22621635     DOI： 10.1056/NEJMc1203704

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

Review 1.  Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.

Authors:  Srdan Verstovsek
Journal:  Postgrad Med       Date:  2013-01       Impact factor: 3.840

Review 2.  Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.

Authors:  Eylem Eliaçık; Ayşe Işık; Salih Aksu; Ayşegül Üner; Yahya Büyükaşık; Nilgün Sayınalp; Hakan Göker; Osman I Özcebe; İbrahim C Haznedaroğlu
Journal:  Turk J Haematol       Date:  2015-06       Impact factor: 1.831
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.